Article
CYP2C19 loss-of-function alleles are not associated with clinical outcome of clopidogrel therapy in patients treated with newer-generation drug-eluting stents.
Medicine - 1 Jun 2016
Choi Ik Jun, Koh Yoon-Seok, Park Mahn-Won, Her Sung Ho, Choi Yun-Seok, Park Chul-Soo, Park Hun-Jun, Kim Pum-Joon, Chung Wook-Sung, Kim Ho-Sook, Shin Jae-Gook, Seung Ki-Bae, Chang Kiyuk
Abstract excerpt
CYP2C19 loss-of-function (LOF) alleles adversely affect clinical outcome of clopidogrel therapy. Recent introduction of a newer-generation drug-eluting stent (DES) has significantly reduced the occurrence of stent thrombosis.The aim of this study was to evaluate the impact of CYP2C19 LOF alleles on clinical outcome in patients treated with the newer-generation DES.The effects of CYP2C19 genotypes were evaluated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
